Report

AstraZeneca invests $2 billion in Summit Therapeutics

STAT reports the companies are teaming up to test ivonescimab, a PD-1/VEGF bispecific drug, alongside AstraZeneca’s antibody-drug conjugates.

1 Source, 20d ago, first seen 20d ago

TLDR

STAT reports AstraZeneca is investing $2 billion in Summit Therapeutics. The companies plan to test ivonescimab alongside AstraZeneca’s antibody-drug conjugates.

Today's Rank

—

Not ranked yet

Combined views

2.6K

1 Source, first seen 20d ago

AstraZeneca invests $2 billion in Summit Therapeutics

TLDR

Combined views

1 Source

Combined views

Sentiment

Summary

Sentiment

Summary

1 Source

1 Source

1 Source

Sentiment

Summary

Sentiment

Summary